Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals
about
Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?Loss of the cytoskeletal protein Pdlim7 predisposes mice to heart defects and hemostatic dysfunctionHIV and SIV Associated Thrombocytopenia: An Expanding Role for Platelets in the Pathogenesis of HIV.Characterization of platelet-monocyte complexes in HIV-1-infected individuals: possible role in HIV-associated neuroinflammation.Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disordersValproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individualsDetection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1.Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B.Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence.Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis.Different resuscitation strategies and novel pharmacologic treatment with valproic acid in traumatic brain injury.Pharmacologic treatment of the ovarian endometrioma.Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.Platelet-derived TGF-β1 mediates the down-modulation of NKG2D expression and may be responsible for impaired natural killer (NK) cytotoxicity in women with endometriosis.Platelets in Immune Response to Virus and Immunopathology of Viral Infections.The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
P2860
Q27010594-45147EB0-CA98-4440-91E2-4014EF7F2A08Q27301488-E85FE638-DA21-4799-BA94-2B97A329E89BQ33401168-3EDAF36A-274B-4260-98DE-D959AB2681FFQ33573879-0E04BA9D-2C62-4A40-9536-395A9596276BQ34517239-4D5173D3-1D96-40C9-A5DB-40C3BFE9330EQ34652709-8FD1E2FE-8512-4A27-A500-74A5876D5918Q35877953-F661D381-F050-4305-A40C-54D26351FD91Q36043123-7C283730-DB96-4C81-891A-E1980B951ECCQ36592411-E6AF5D74-8E38-419D-A316-04BFDD0618BBQ37326252-74A187DC-0EBE-447C-9647-54FD049EB20EQ38293603-DCA15AAC-E9A7-4B3C-95E8-8747D595A55FQ38652105-6C74DE53-2BCD-4624-9A85-942DDAFF7E88Q38822468-6593C8E6-AFFB-4BF4-9D0B-15B8FDD1E963Q42212835-5D7CE89A-AFE9-4B98-9CBE-E392CE694A99Q53613478-42A14B14-FACD-4E05-92D2-E88D98CF661AQ55004062-53563506-F67B-4091-B125-A1DAB4F11CE9Q57166290-6BA9C956-9A70-402C-A312-BBECE5888DDA
P2860
Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@ast
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@en
type
label
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@ast
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@en
prefLabel
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@ast
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@en
P2093
P2860
P356
P1476
Antiplatelet activity of valpr ...... IV type 1-infected individuals
@en
P2093
Craig N Morrell
Donna C Davidson
Giovanni Schifitto
Michael P Hirschman
Richard P Phipps
Sanjay B Maggirwar
Sherry L Spinelli
P2860
P304
P356
10.4049/JIMMUNOL.1001911
P407
P577
2010-11-29T00:00:00Z